Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
网页1 天前 · Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse ...
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
网页1 天前 · Earlier on Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist. After ...
News Details - novonordisk.com
网页1 天前 · Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 . The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose of monlunabant compared to placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome 1 .
Monlunabant phase 2a trial in obesity successfully completed
网页News & Events. Latest releases; Monlunabant phase 2a trial in obesity successfully completed. Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV …
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
网页1 天前 · Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 [Link].The trial investigated the efficacy and safety of a once-daily 10 ...
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
网页1 天前 · The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose of monlunabant compared to placebo on body weight after 16 weeks in 243 people with obesity and metabolic ...
Novo’s Next-Gen CB1 Drug Leads to Weight Loss in Phase II, but ...
网页1 天前 · The trial examined three doses of monlunabant in 243 patients, and the average weight loss of 15 lbs was achieved in the lowest dose arm, where patients received 10 mg. Novo said that “limited additional weight loss was seen at higher doses of monlunabant.” ... BioSpace is the digital hub for life science news and jobs. We provide essential ...
Novo Nordisk’s obesity newcomer monlunabant heads into …
网页1 天前 · Novo Nordisk has now announced headline results from a Phase IIa trial with monlunabant investigating the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose compared to placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome. People were equally randomized among the four treatment arms.
Novo Nordisk Slips On Phase 2a Clinical Trial Result With Monlunabant
网页1 天前 · Friday, shares of Novo Nordisk A/S are sliding following the announcement of safety results of phase 2a clinical trial of Monlunabant compared to placebo in patients with obesity and metabolic syndrome.Monlunabant, formerly INV-202, is a small molecule oral cannabinoid receptor 1 or CB1 inverse agonist. The trial investigated efficacy and safety, and post 16 weeks, people treated with a once ...
Novo Nordisk Stock Declines After Headline Results From Mid …
网页1 天前 · Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant ...
- 某些结果已被删除
跳至内容